Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals. by Gichuhi, Stephen & Irlam, James H
Gichuhi, S; Irlam, JH (2013) Interventions for squamous cell car-
cinoma of the conjunctiva in HIV-infected individuals. Cochrane
Database Syst Rev, 2. CD005643. ISSN 1469-493X DOI: 10.1002/14651858.CD005643.pub3
Downloaded from: http://researchonline.lshtm.ac.uk/2019624/
DOI: 10.1002/14651858.CD005643.pub3
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
Cochrane Database of Systematic Reviews
Interventions for squamous cell carcinoma of the conjunctiva
in HIV-infected individuals (Review)
Gichuhi S, Irlam JH
Gichuhi S, Irlam JH.
Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals.
Cochrane Database of Systematic Reviews 2013, Issue 2. Art. No.: CD005643.
DOI: 10.1002/14651858.CD005643.pub3.
www.cochranelibrary.com
Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
5OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
7DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
13ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iInterventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Interventions for squamous cell carcinoma of the conjunctiva
in HIV-infected individuals
Stephen Gichuhi1, James H Irlam2
1Department of Ophthalmology, University of Nairobi, Nairobi, Kenya. 2Primary Health Care Directorate, University of Cape Town,
Cape Town, South Africa
Contact address: StephenGichuhi, Department of Ophthalmology,University of Nairobi, P.O Box 347, KNH,Nairobi, 00202, Kenya.
sgichuhi@wananchi.com. sgichuhi@uonbi.ac.ke.
Editorial group: Cochrane HIV/AIDS Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 2, 2013.
Review content assessed as up-to-date: 19 February 2007.
Citation: Gichuhi S, Irlam JH. Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals. Cochrane
Database of Systematic Reviews 2013, Issue 2. Art. No.: CD005643. DOI: 10.1002/14651858.CD005643.pub3.
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Squamous cell carcinoma of the conjunctiva is described in the ophthalmic literature as a rare, slow-growing tumour of the eye, normally
affecting elderly men around 70 years of age. In Africa, however, the disease is different. The incidence is rising rapidly, affecting young
persons (around 35 years of age), and usually affecting women. It is more aggressive, with amean history of threemonths at presentation.
This pattern is related to the co-existence of the HIV/AIDS pandemic, high HPV exposure, and solar radiation in the region. Various
interventions exist, but despite therapy, there is a high recurrence rate (up to 43%) and poor cosmetic results in late disease. This review
was conducted to evaluate the interventions for treatment of conjunctival squamous cell carcinoma in HIV-infected individuals.
Objectives
To evaluate the effect of interventions for treating squamous cell carcinoma of the conjunctiva in HIV-infected individuals on local
control, recurrence, death, time to recurrence, and adverse events.
Search methods
Using a sensitive search strategy, we attempted to identify all relevant trials, regardless of language or publication status, from the
following electronic databases; PubMedPubMed, EMBASE and The Cochrane Library. We also searched clinical trial registries; WHO
International Clinical Trials Registry Platform (ICTRP) and the US National Institutes of Health Clinicaltrials.gov. We searched the
international conference proceedings of HIV/AIDS and AIDS-related cancers from the AIDS Education Global Education System
(AEGIS). Searches were conducted between January and February 2012.
Selection criteria
Randomised controlled trials (RCTs) involving HIV-infected individuals with ocular surface squamous neoplasia.
Data collection and analysis
We independently screened the results of the search to select potentially relevant studies and to retrieve the full articles.We independently
applied the inclusion criteria to the potentially relevant studies. No studies were identified that fulfilled the selection criteria.
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Main results
No RCTs of interventions currently used against conjunctival squamous cell carcinoma in HIV-infected individuals were identi-
fied.There is one ongoing RCT in Kenya that was registered in July 2012.
Authors’ conclusions
Implications for practice:
Current clinical practice in treatment of squamous cell carcinoma of the conjunctiva rests on a weak evidence base of case series and
case reports.
Implications for research:
Randomised controlled trials for treatment of this disease are needed in settings where it occurs most frequently. Preventive interventions
also need to be identified. HIV/AIDS research has not focused on treatment of this tumour.
P L A I N L A N G U A G E S U M M A R Y
Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Conjunctival squamous cell carcinoma, a tumour of the thin membrane that covers the white of the eye, is becoming more common,
more aggressive, and affectingmore young people, especially women. This pattern is associated with theHIV/AIDS pandemic, exposure
to solar radiation, and infection with human papilloma virus (HPV). Various treatment modalities exist, but the recurrence rate is high
and the cosmetic outcome of late disease unsightly (Figure 1). Death may occur when the disease spreads to the surrounding structures
and the brain. This review was conducted to evaluate the effects of the current interventions. No randomised controlled trials of any
interventions for this cancer were found. Current clinical practice appears to be based on case series and case reports. These are weak
sources of evidence for the effectiveness of a treatment. Randomised controlled clinical trials are needed.
B A C K G R O U N D
Definition
Squamous cell carcinoma of the conjunctiva (SCC) is the end stage
of a spectrumof conditions called ocular surface squamous neopla-
sia (OSSN). Histologically, OSSN varies from a benign form that
includes papilloma, pseudoepitheliomatous hyperplasia and be-
nign hereditary intraepithelial dyskeratosis, through a pre-invasive
form called conjunctival intraepithelial neoplasia (CIN) graded as
I,II or III depending on depth of involvement and finally the in-
vasive form that includes squamous cell carcinoma and mucoepi-
dermoid carcinoma (Basti 2003).When the dysplastic changes are
confined to the basal one third of the epithelium, this is termed
CIN I or mild dysplasia, when they extend into the middle third
of the epithelium this is termed CIN II or moderated dysplasia
and when they extend into the superficial third of the epithelium
this is termed CIN III or severe dysplasia. Full thickness dysplasia
is also referred to as carcinoma-in-situ (CIS). Invasive squamous
cell carcinoma of the conjunctiva refers to the infiltration through
the basement membrane to involve the underlying stroma (Basti
2003; Shields 2004). Clinically, these stages may be indistinguish-
able except by histology.
Clinical features
The tumour may be asymptomatic or present with redness, irrita-
tion, severe pain, and visual loss (Tunc 1999). It commonly affects
the visible area between the upper and lower eyelids (interpalpe-
bral conjunctiva), usually on the nasal side at the margin of the
conjunctiva and the cornea (limbus). This slow-growing tumour
can present as a solitary or diffuse growth. Solitary tumours can
be nodular or gelatinous and may have a whitish plaque (leuko-
plakia). The lesionmimics benign conjunctival degenerations such
as pterygium and pinguecula. Most cases are unilateral(Cervantes
2002; Chisi 2006).
The morbidity from squamous cell carcinoma of the conjunctiva
relates to the effects of the disease and its treatment. It may ex-
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tend into the eyeball, orbit, regional lymph nodes, surrounding
paranasal sinuses and the brain. Death may result from regional
or distant metastases, as well as intracranial spread.
Aetiology
The aetiology of SCC has been associated with HIV infection
(Ateenyi-Agaba 1995;Waddell 1996), human papilloma virus
(HPV) infection (Waddell 1996;Nakamura 1997;Newton 2002),
immunosuppression in organ transplant recipients (Macarez
1999), and exposure to ultraviolet B rays of the sun (Ateenyi-Agaba
2004; Ng 2008; ). Chronic conjunctival diseases, such as aller-
gic conjunctivitis and trachoma, have also been implicated (Poole
1999).
The majority of affected persons in Africa are HIV-positive; 71%
in Uganda, 86% in Malawi (Waddell 1996) ,70.6% in South
Africa (Mahomed 2002) and 75% in Nigeria (Osahon 2011). In
a smaller study in Zimbabwe, 12 out of 13 persons with SCC or
CIS (92.3%) were HIV-positive (Porges 2003). Many ophthal-
mologists in Africa now consider SCC in young adults to be a
marker for HIV infection. The relationship between SCC and
HPV is less clear. Some case-control studies have found an as-
sociation (Moubayed 2004; de Koning 2008) while some have
not (Sen 2007; Guthoff 2009). Among HIV-infected people with
SCC, cutaneous types of HPV are detected more frequently than
the mucosal types (de Koning 2008; Ateenyi-Agaba 2010). In
another Ugandan study, HPV was detected more frequently in
the low-grade conjunctival neoplasias than in more advanced dis-
ease (Tornesello 2006). Ultraviolet solar radiation causes tissue
damange mediated through mutation of the tp53 tumour-sup-
pressor gene and tissue matrix metalloproteinases (Ateenyi-Agaba
2004; Ng 2008).
It is plausible that the aetiology involves an interaction of these
factors in a yet to be determined model.
Epidemiology
The epidemiology of SCChas transformed in the last few decades.
It used to be an uncommon slow-growing tumour found in elderly
males (Lee 1997; McKelvie 2002), but in Africa it is becoming
more common, more aggressive, and more likely to affect young
persons, especially females (Ateenyi-Agaba 1995). This pattern is
related to the co-existence of theHIV/AIDS pandemic, high HPV
exposure, and solar radiation in the region. The HIV pandemic
is mainly centered in Africa. In 2009 22.5 million of the 33.3
million infected people worldwide were living in Africa (UNAIDS
2010). Africa also has the highest prevalence of HPV infection in
the world, with an age-adjusted prevalence of 25.6% in women
of age 15 to 74 years, followed by South America (14.3%), Asia
(8.7%) and Europe (5.2%). (Clifford 2005). The equator bissects
the continent and over 75% of the continent is within the tropics
with consequent high ambient solar exposure all year round.
The Kampala Cancer Registry in Uganda recorded a six-fold in-
crease in the incidence of conjunctival squamous cell carcinoma,
from an average of six per million per year between 1970 and
1988, to 35 per million per year in 1992 (Ateenyi-Agaba 1995).
A study in Australia found that 78.5% of affected persons were
elderly males with a mean age of 60 years (Lee 1997). Similarly,
in Britain, 77% were males and 69% of them were more than
60 years old (McKelvie 2002). In contrast, a study in Zimbabwe
found that 70% of patients were young females with a median
age of 35 years (Pola 2003), while in South Africa the mean age
was 37 years (Mahomed 2002). In Tanzania the tumour has been
observed to be more aggressive than it was previously. The mean
length of history on presentation is three months (Poole 1999).
SCC is a common tumour of the ocular surface among adults in
Africa. Pola 2003 In Tanzania 45.8% of 168 conjunctival biopsies
seen between 1996 and 1997 were squamous cell carcinomas,
while 35% were pingueculum or pterygium (Poole 1999).
The prevalence of SCC in a hospital-based HIV-positive popula-
tion in Kenya was 7.8% (Chisi 2006).
Diagnosis
Most cases are diagnosed on clinical impression after a person
presents with a growth on the eyeball, which is then excised and
sent for histology to get a definitive diagnosis (Shields 1997).
Histopathology is the commonest mode of diagnosis in practice.
Although regarded as the gold standard, histopathological diag-
noses are subject to discordant interpretation (Margo 2002). Cy-
tology has also been used, especially for the follow-up of people
treated using chemotherapy or immune therapy to monitor re-
currence, since malignant cells are poorly adherent to each other
(McKelvie 2001).
Other methods include the use of DNA cytometry to identify tu-
mour-cell regression (Nadjari 1999); immunostaining for certain
molecular genetic markers, such as proliferating cells nuclear anti-
gens (PCNA), Ki67 expression, tp53 gene mutations, and argy-
rophilic nucleolar organiser regions (AgNORs) (Aoki 1998); and
toluidine blue staining to mark tumour margins for surgical exci-
sion (Kaji 2006).
Treatment options
The treatment of this condition since the pre-HIV era has been
simple: surgical excision alone or with additional adjunctive ther-
apy. The main objective of surgical excision is complete removal
of the tumour to minimise recurrence (Shields 1997). The result-
ing surface defect may need reconstruction using amniotic mem-
brane transplantation (Espana 2002; Gunduz 2005) or limbal au-
tografts (Copeland 1990). Adjunctive therapies augment surgical
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excision. These include cryotherapy, chemotherapy, radiotherapy,
immune therapy, and amniotic membrane transplants. They work
by killing residual malignant cells at the excision margins or any
that may be seeded during excision, although there are also re-
ports of their use as primary therapy (Cerezo 1990; Karp 2001;
Barbazetto 2004). Cidofovir, an antiviral active against human pa-
pilloma virus, has been described as a primary therapy, and was
reported to cause tumour regression (Sherman 2002). It under-
goes phosphorylation to active diphosphates independent of viral
enzymes, which act as both inhibitors and alternative substrates
of viral DNA polymerase, thus inhibiting DNA synthesis (Safrin
2004). A list of these interventions is shown in Table 1.
Cryotherapy kills malignant cells by repeated cycles of freezing
and thawing (Peksayar 1989). Chemotherapy involves using a class
of drugs called antimetabolites. They act by interfering with the
enzymes involved in the intermediary metabolism of replicating
cancer cells. An example is 5-Fluorouracil (5-FU) and mitomycin
C. The former (5-FU), is a prodrug, which means it is converted
to active molecules. One of them, 5- fluoro-2’- deoxyuridine-5’-
monophosphate (FdUMP), binds to the enzyme thymidylate syn-
thetase critical for the synthesis of thymidylate, which results in
the inhibition ofDNA synthesis. Another one, 5-fluorouridine-5’-
triphosphate (FUTP) interferes with RNA synthesis (Chu 2004).
It is cell-cycle specific and acts in the S phase of the cell cycle. In
one study, 1% 5-FU eyedrops were used alone without concur-
rent surgery or radiotherapy to treat a recurrent tumour (Midena
2000). Mitomycin C is an antibiotic which acts by interfering
with the DNA of tumour cells. It undergoes metabolic activation,
which generates an alkylating agent that cross-links DNA,making
the cell unable to replicate (Chu 2004). It is a cycle-non-specific
agent that is most effective in the G1 and S phases. Radiotherapy
destroys the DNA and RNA of dividing cells (Goldberg 1963).
The source of beta radiation is strontium 90 (Cerezo 1990). Pho-
todynamic therapy combines a drug (called a photosensitizer or
photosensitizing agent) with light of a specific wavelength to pro-
duce activated oxygen species that promote tumour destruction
(Castano 2005). Another treatment option is amniotic membrane
transplantation. It is one of the layers of the placenta and is ob-
tained after electiveCaesarean section. It has anti-angiogenic, anti-
scarring, and anti-inflammatory properties (Hao 2000). Immune
therapy for this condition involves the use of interferon alpha.
Interferon alpha is part of a group of proteins called cytokines. It
has three-pronged action with antiviral and oncostatic effects and
also activates natural killer cells, which are cells of the immune
system that are able to recognise and destroy tumour cells (Lake
2004). The exact mechanism of action is not known. Cidofovir,
an antiviral that is active against human papilloma virus, has been
reported to cause regression of this tumour (Sherman 2002). It
undergoes phosphorylation to active diphosphates independent of
viral enzymes, which act as both inhibitors and alternative sub-
strates of viral DNA polymerase, thus inhibiting DNA synthesis
(Safrin 2004).
Advanced disease where the tumour has spread requires removal
of the eyeball (modified enucleation) or the entire orbital contents
(exenteration) in an attempt to save life (Shields 1991).
Despite therapy, up to 43% of treated patients experience recur-
rence at variable times (but usually within two years) (Peksayar
1989; Tabin 1997; Yeatts 2000). Simple excision has a higher rate
of recurrence. A study inAustralia reported 23%(Lee 1997). In the
USA, it was 28.5%, but was 7.7% when combined with cryother-
apy (Sudesh 2000). In one series of 17 cases treated with mito-
mycin C eye drops, 15 of them had undergone one to four surgi-
cal procedures before the mitomycin C treatment and six (35%)
recurred within six months (Frucht-Pery 1997). The efficacies of
treatment reported in the literature need to be interpreted cau-
tiously, since some of the treated cases have recurrences from prior
surgical excision (Frucht-Pery 1997; Midena 2000). The recur-
rence rate may be higher in Africa due to late presentation, expo-
sure to solar radiation, and lack of many of the adjunctive thera-
pies. Only cryotherapy and chemotherapy are likely to be found
in advanced centres.
It is not clear whether the efficacy of these interventions is dif-
ferent in people with HIV infection. The effect, if any, of highly
active antiretroviral therapy (HAART) on this condition is also
not clearly known.
Clinical and public health importance of this review
Although the number of people living with HIV infection world-
wide seems to have stabilized Africa remains the global epicentre
of the AIDS pandemic (UNAIDS 2010). The region also has the
highest prevalence of HPV in the world and high solar ultraviolet
exposure year-round (Clifford 2005). If this triad of risk factors
remains, the number of cases of conjunctival squamous cell carci-
noma is expected to remain high. The effect of HPV vaccination
in children on OSSN if any will take a long time to determine.
Recurrences still occur after surgical excision. Most of the cur-
rent adjunctive therapies described are not readily available in low-
income countries. They are expensive and inconvenient to use.
Cryotherapy requires special probes and canisters of liquid nitro-
gen gas that need refilling. Amniotic membrane transplantation
requires tissue banks to process and preserve the transplant mate-
rial. Medications for chemotherapy are not widely available, but
are probably the easiest to obtain and use in such settings, since
they are packed in small vials and do not require stringent storage
conditions.
The cosmetic outcome of advanced disease and its treatment is
very poor and leaves patients with an empty socket (Figure 1).
Patients who undergo orbital exenteration often experience social
problems because of their facial disfigurement leading to limited
social interaction (Bonanno 2010). Facilities for cosmetic surgery
and orbital implants in low-income countries are often unavail-
able.
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Figure 1.
With antiretroviral therapy, HIV-infected people can now enjoy
an improved physical appearance and quality of life, but unsightly
lesions on the face such as those caused by conjunctival squa-
mous cell carcinoma unmask what would otherwise be a ’hidden’
HIV infection. This potentially exposes the affected persons to the
stigma and discrimination associated with HIV infection.
Effective evidence-based interventions that allow early diagnosis
and treatment are therefore needed.
O B J E C T I V E S
To evaluate interventions for treating squamous cell carcinoma of
the conjunctiva in HIV-infected individuals (see Table 1 for list
of interventions).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCT).
Types of participants
HIV-positive people with ocular surface squamous neoplasia
(OSSN), whose diagnosis of HIV infection is based on either an-
tibody or antigen tests, and whose OSSN is determined by histol-
ogy, conjunctival impression cytology, or immunostaining.
Types of interventions
Any intervention used for treatingOSSN, including the following:
• surgical excision, modified enucleation, and exenteration
• adjunctive therapies such as cryotherapy, chemotherapy,
radiotherapy, amniotic membrane transplants , and immune
therapies, such as interferon therapy
• cidofovir
• different regimens of HAART
• combinations of the above
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We were interested in trials that compared any of the interven-
tions with another intervention or a placebo, or trials comparing
different dosages or regimens of the same intervention.
Types of outcome measures
Primary outcomes
• local control, defined as a tumour-free period of two years
• recurrence at six months, then at six-month intervals
thereafter until two years after treatment, diagnosed by
histopathology, conjunctival impression cytology, or
immunostaining
• death
Secondary outcomes
• time to recurrence
• adverse events
Search methods for identification of studies
The HIV/AIDS review group search methods were used. We
searched electronic databases and abstracts of conference proceed-
ings. There were no language restrictions. The key words used in
the search included:
ocular surface squamous neoplasia, squamous cell carcinoma, con-
junctiva, carcinoma in situ, conjunctival intraepithelial neoplasia,
HIV, AIDS, excision, enucleation, exenteration, chemotherapy,
cryotherapy, interferon, immunetherapy, radiotherapy,
A search had been conducted in December 2009 using search
terms from the first edition of this review and found no trials. We
conducted an updated search beginning January 2010.
• Electronic databases
The following electronic databases were searched.
1. PubMed - from January 2010 to 27th January 2012
2. EMBASE - from January 2010 to 10th February 2012
3. The Cochrane Library - from January 2010 to 3rd February
2012
• Clinical trial registers
We searched theWHO International Clinical Trials Registry Plat-
form (ICTRP) on 10th February 2012 (WHO ICTRP 2012).We
also searched the clinical trial register of the USNational Institutes
of Health (NIH) www.clinicaltrials.gov website (NIH 2012) on
12th February 2012. This database includes trials registered with
the US National Eye Institute (NEI) and US National Cancer In-
stitute (NCI).
• Conference proceedings
We searched abstracts of the proceedings of the HIV/AIDS con-
ferences covered in the AIDS Education Global Education System
(AEGIS) database (http://www.aegis.com/search).
This search covered all the following conferences which also shows
the latest conference abstracts available in the AEGIS database:
1. International AIDS conference by the the International AIDS
Society (IAS) upto the conference held from 18th-23rd August
2010
2. International AIDS Society (IAS) HIV Pathogenesis and Treat-
ment upto the 5th conference held from 19th-22nd July 2009
3. International Congress onDrug Therapy inHIV infection upto
the 9th meeting on 9th-13th November 2008
4. International Workshops on Adverse Drug Reactions and
Lipodystrophy in HIV upto the 11th workshop on 26th-28th Oc-
tober 2009
5. Conference on Retroviruses and Opportunistic Infections
(CROI) upto the 15th conference on 3rd-6th February 2008
6. Centers for Disease Control and Prevention (CDC) National
HIV Prevention conference upto the meeting on 12th-15th June
2005
7. The International Workshops on HIV Drug Resistance and
Treatment Strategies upto the 5th workshop on 4th-8th June 2001
8. British HIV Association (BHIVA) upto the 17th conference
held on 6th to 8th April 2011
9. European AIDS Clinical Society upto the 11th conference held
on 24th-27th October 2007
10. National HIV/AIDS Update Conference upto the 17th con-
ference on 10th-13th April 2005
• Reference lists
We checked the reference lists of all studies identified by the above
methods for additional relevant records.
Data collection and analysis
We independently screened the results of the search to select po-
tentially relevant studies and to retrieve the full articles (Table 2).
Where there was any uncertainty we obtained the full article. We
independently applied the inclusion criteria using a specially de-
signed eligibility form to the potentially relevant studies. No ran-
domised controlled trials met the inclusion criteria.
R E S U L T S
Description of studies
See: Characteristics of ongoing studies.
No studies were identified that fulfilled the selection criteria. The
PRISMA flowchart in Figure 2 summarizes the results (Figure
2). There is an ongoing study in Kenya that was registered in
the PanAfrican Clinical Trials Register on 19th July 2012. This
register feeds into theWHO International Clinical Trials Registry
Platform (ICTRP).
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Figure 2. PRISMA study flow diagram.
Risk of bias in included studies
No studies were identified that fulfilled the selection criteria.
Effects of interventions
No studies were identified that fulfilled the selection criteria. The
search strategy yielded 12 records, which were all excluded (see
table of excluded studies).
D I S C U S S I O N
In this review no randomised controlled trials on the effectiveness
of interventions against conjunctival squamous cell carcinoma in
HIV-infected individuals were identified. No randomised con-
trolled trials were found, even in theHIV-uninfected populations.
Current practice is based on the results of interventional case se-
ries and case reports (Table 1). The quality of evidence from these
study designs ranks low by various systems for grading evidence.
It is graded level four by the Oxford Centre for Evidence-Based
Medicine (OECBM) recommendations (Phillips 2001) and low-
grade by the Grading of Recommendations Assessment, Develop-
ment and Evaluation (GRADE) Working Group (Atkins 2004).
According to GRADE, low means that further research is very
likely to have an important impact on our confidence in the esti-
mate of effect and is likely to change the estimate. These studies
are also mainly from western countries, where the participants are
usually elderlymales, who have a different disease profile from par-
ticipants in developing countries. They have a less aggressive form
of the disease and few are HIV-infected (Ateenyi-Agaba 1995;
Waddell 1996; Lee 1997; Poole 1999; Mahomed 2002; McKelvie
2002). We could not explain why there are no trials, but postulate
that perhaps it reflects differences in research priorities, since the
prevalence of this tumour is low among HIV-infected individuals
living in the western world.
There is a need to conduct randomised controlled trials to provide
unbiased evidence for the effectiveness of currently used interven-
tions for treating conjunctival squamous cell carcinoma. Ideally,
the disease would be studied in its early stages, before it has spread,
since in the later stages the treatment is more costly, can only be
provided in tertiary care centres, and would tend to be individu-
ally tailored depending on the extent of spread. Studies are needed
in the setting where the greatest burden of disease is found. The
typical setting involves young HIV-infected individuals, mostly
females with aggressive disease and HIV co-infections, in the con-
text of high HIV prevalence, high solar exposure, and limited re-
sources.
Investigating the effectiveness of simple surgical excision versus
wide excision with or without adjunctive antimetabolite eye drops
would be relevant as these are relatively simple interventions that
can be easily translated in developing countries. The effect of new
health technologies used in the developed world, such as cryother-
apy, amniotic membrane transplants, and photodynamic therapy,
should also be assessed in RCTs.
Preventive interventions directed against the mutagenic effects of
solar ultraviolet B radiation and the oncogenic viruses associated
with this disease also need to be identified.
There is also an important implication for diagnostic tests for
early disease. Ethical issues that may arise include, for instance,
whether participants should be subjected to the application of
potentially dangerous cytotoxic antimetabolites as an adjunct to
excisionbiopsy before there is histological confirmation of tumour.
Treatment of conjunctival squamous cell carcinomas with topical
mitomycin C and/or radiation has been associated with induction
of atypical cell changes, such as conjunctival DNA-polyploidy
afterward (Cartsburg 2001). More sensitive diagnostic tests, such
as cytology or immunostaining, may thus need to be used pre-
operatively.
Treatment of opportunistic tumours in HIV/AIDS, such as squa-
mous cell carcinoma of the conjunctiva, is part and parcel of HIV
care.Untreated squamous cell carcinomaof the conjunctiva threat-
ens survival. Not paying attention to this disease may compromise
the gains from other care availed to affected individuals.
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current clinical practice in treatment of squamous cell carcinoma
of the conjunctiva is based on case series and case reports. This is
a weak evidence base.
Implications for research
RCTs for treatment of this disease are needed in the settings where
it occurs most frequently. Preventive interventions, such as HPV
vaccination, also need to be identified once scientific knowledge
of the serotypes involved is established. HIV/AIDS research has
not focused on treatment of this tumour.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of ongoing studies [ordered by study ID]
Gichuhi 2012
Trial name or title Adjuvant topical 5fluorouracil (5FU) for ocular surface squamous neoplasia
Methods In this randomized controlled trial tumours involving less than 2 quadrants of the conjunctiva that are
suspected to be OSSN will be surgically excised
Participants Adults with histologically proven OSSN whose tumour excision site has healed
Interventions Topical 1% 5-Fluorouracil in artificial tears vs artificial tears applied 6 hourly for one month
Outcomes Primary: Development of histopathologically confirmed recurrent OSSN anytime during the first year after
the primary surgery
Secondary: Adverse effects of using topical 5-FU 1% four times daily for one month
Starting date 23/8/2012
Contact information sgichuhi@uonbi.ac.ke
Notes
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. 2 Interventions used in treatment of conjunctival squamous cell carcinoma
Intervention Description Reference
Surgical excision Alcohol epitheliectomy for the corneal
component and partial lamellar sclerocon-
junctivectomy with 3 to 4mm margins for
the conjunctival component. Frozen sec-
tions may be used to ensure tumour-free
margins. Modified enucleation involves re-
moving the affected conjunctiva with a
4mmmargin together with the eyeball. Ex-
enteration involves complete removal of or-
bital tissue including the periosteum of the
bony walls. The eyelids may or may not be
spared
Shields 1997 Shields 2004
Cryotherapy Freeze-thaw-freeze-thaw (double freeze-
thaw) applying probe to the excised con-
junctival margin
Peksayar 1989
Chemotherapy
- 5 Fluorouracil (5FU) 1% solution
- Mitomycin C 0.02% or 0.04%
As topical solutions to soak operated site for
2-5 minutes, as subconjunctival injection
intra- or post operatively or as eyedrops to
be applied post-operatively as follows
4 times daily for 1-2 weeks or as pulsed
therapy giving 4 applications for 4 days re-
peated every month for 4-6 cycles
4 times daily for 2 weeks then repeat at 4-
6 weeks intervals depending on response
Yeatts 2000
Midena 2000
Frucht-Pery 1997
Radiotherapy - beta irradiation
- gamma irradiation
- photodynamic therapy
Cerezo 1990
Goldberg 1963
Barbazetto 2004
Amniotic membrane transplants (AMT) Excise tumour with a 3-4 mm tumour-free
margin (so frozen sections needed), apply
cryotherapy to the margin then to close the
defect suture amniotic membrane with 8/0
vicryl sutures to adjacent conjunctiva and
to adjacent cornea using 10/0 nylon sutures
with epithelial side facing up
Gunduz 2005
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Table 1. 2 Interventions used in treatment of conjunctival squamous cell carcinoma (Continued)
Interferon alpha 2b Topical drops or intralesion injection Karp 2001
Cidofovir eyedrops 2mg/ml Applied every 2 hours for 2 weeks then 4
times daily for 2 weeks then 3 times daily
for 2 weeks
Sherman 2002
Table 2. 1 Review methods
Study selection The titles and abstracts of search results are scanned and compared to
predetermined selection criteria for studies. Articles written in foreign
languages are translated to English. Two authors working independently
select trials. The authors are blinded to the trial uthors and institutions
by asking the trial search co-ordinator to block this out when sending
abstracts. Where there is uncertainty about inclusion, the full text of the
article is obtained and read. If additional information is needed about
the trial in question, it is categorized as awaiting assessment until this is
obtained. If differences arise regarding trial inclusion, they are discussed
and if still unresolved, Dr Taryn Young at the South African Cochrane
Centre is asked to take a decision
Data extraction Data are collected and recorded in similar data extraction forms. The fol-
lowing information is extracted; citation details, study eligibility, study
quality and study characteristics. The study characteristics include meth-
ods, participants, interventions and outcomes
Assessment of methodological quality of included studies The methodological quality of the included studies is assessed to deter-
mine validity. Selection bias is checked by assessing whether the gener-
ation of a random allocation sequence and allocation concealment were
performed. Randomization is considered adequate if the allocation se-
quence is generated from a table of random numbers or by computer.
Allocation concealment is deemed adequate if undertaken by means of
sequentially prenumbered sealed opaque envelopes, a centralised system
or prenumbered coded identical containers. In addition, assessment of
blinding, losses to follow-up and whether the analysis was by intention-
to-treat (ITT) is undertaken. The definition of ITT is the requirement
that participants be analyzed in the groups to which they were random-
ized, regardless of which intervention they actually received
Data analysis Measures of treatment effect:The effect measures of choice here are rela-
tive risk (RR) for dichotomous data and hazard ratio (HR) for time-to-
event data with a 95% confidence interval
Dichotomous data include: - number of people who experience local
control in each comparison group
- number of people who experience recurrence during the specified time
periods in each comparison group
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Table 2. 1 Review methods (Continued)
- number of deaths in each comparison group
- number of people who experience adverse events in each comparison
group
- number of people who experience local control in each comparison
group
- number of people who experience recurrence during the specified time
periods in each comparison group
- number of deaths in each comparison group
- number of people who experience adverse events in each comparison
group
Time-to-event data include: - time to recurrence
Dealing with missing data: Participants lost to follow up are censored in
the survival analysis
Assessment of heterogeneity: To identify statistical heterogeneity we look
at the forest plot for overlapping confidence intervals and test it using
the Cochrane Q test with a p-value of 0.10. The impact of heterogeneity
on the meta-analysis is measured using the I-squared test. If I-squared
is greater than 70% we will investigate by checking the trials for data
entry errors and looking for existence of subgroups. Subgroup analysis
by age, sex, geographical location and diagnostic method will be done.
These factors have been shown to influence the occurrence of OSSN
and we anticipate that they may also influence treatment effects. If no
explanation for heterogeneity is found or its correction is not possible,
meta-analysis will not be done
Meta-analysis: A fixed-effect model is used for meta-analysis but when
there is heterogeneity that cannot be readily explained, a random-effects
model is incorporated
Sensitivity analysis: We examine how the magnitude of effect differs
according to study quality or trial size and also the results of per-protocol
analysis with those of intention-to-treat analysis
Assessment of reporting bias: Publication bias is assessed by using a funnel
plot to look for asymmetry
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A P P E N D I C E S
Appendix 1. PubMed search strategy and results
Title: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Database: PubMed (2010 - 2012)
Date: 27 January 2012
Search Query Items found
#13 Search #1 AND #2 AND #11 AND (“2010/10/01”[Date -
Publication] : “2012/01/27”[Date - Publication])
4
#12 Search #1 AND #2 AND #11 23
#11 Search #9 OR #10 2290
#10 Search conjunctival neoplasms[mh] 1729
#9 Search #5 AND #8 1099
#8 Search #6 OR #7 546016
#7 Search carcinoma[tiab] OR carcinomas[tiab] OR neopla-
sia[tiab] OR neoplasm[tiab] OR neoplasms[tiab]
514787
#6 Search carcinoma, squamous cell[mh] 92643
#5 Search #3 OR #4 23573
#4 Search conjunctiva[tiab]ORconjunctivas[tiab]ORconjunc-
tival[tiab]
18906
#3 Search conjunctiva[MeSH Terms] 11829
#2 Search (randomized controlled trial [pt] OR controlled clin-
ical trial [pt] OR randomized [tiab] OR placebo [tiab] OR
drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR
groups [tiab]) NOT (animals [mh] NOT humans [mh])
2499392
#1 SearchHIV Infections[MeSH]ORHIV[MeSH]ORhiv[tw]
OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw]
OR hiv infect*[tw] OR human immunodeficiency virus[tw]
OR human immunedeficiency virus[tw] OR human im-
muno-deficiency virus[tw] OR human immune-deficiency
virus[tw] OR ((human immun*) AND (deficiency virus[tw])
) OR acquired immunodeficiency syndrome[tw] OR ac-
quired immunedeficiency syndrome[tw] OR acquired im-
muno-deficiency syndrome[tw] OR acquired immune-defi-
ciency syndrome[tw] OR ((acquired immun*) AND (defi-
ciency syndrome[tw])) OR “sexually transmitted diseases, vi-
282439
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(Continued)
ral”[MH:noexp]
Appendix 2. EMBASE search strategy and results
Title: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Database: PubMed (2010 - 2012)
Date: 10 February 2012
No. Query Results
#13 #1 AND #2 AND #11 AND [humans]/lim AND [embase]/
lim AND [1-2-2012]/sd NOT [10-2-2012]/sd
0
#12 #1 AND #2 AND #11 4
#11 #9 OR #10 2964
#10 ’conjunctiva tumor’/syn 1802
#9 #5 AND #8 1796
#8 #6 OR #7 646277
#7 carcinoma:ab,ti OR carcinomas:ab,ti OR neoplasia:ab,ti OR
neoplasm:ab,ti OR neoplasms:ab,ti
617186
#6 ’carcinoma, squamous cell’/syn 110025
#5 #3 OR #4 56567
#4 conjunctiva:ab,ti OR conjunctivas:ab,ti OR conjunctival:ab,
ti
22041
#3 ’conjunctiva’/syn 51682
#2 random*:ti OR random*:ab OR factorial*:ti OR factorial*:
ab OR cross?over*:ti OR cross?over:ab OR crossover*:ti OR
crossover*:ab OR placebo*:ti OR placebo*:ab OR (doubl*:ti
AND blind*:ti) OR (doubl*:ab AND blind*:ab) OR (singl*:
ti AND blind*:ti) OR (singl*:ab AND blind*:ab) OR as-
sign*:tiORassign*:abORvolunteer*:tiORvolunteer*:abOR
’crossover procedure’/de OR ’crossover procedure’ OR ’dou-
ble-blind procedure’/deOR ’double-blind procedure’OR ’sin-
gle-blind procedure’/de OR ’single-blind procedure’ OR ’ran-
domized controlled trial’/de OR ’randomized controlled trial’
OR allocat*:ti OR allocat*:ab
1186635
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(Continued)
#1 ’human immunodeficiency virus infection’/exp OR ’human
immunodeficiency virus infection’ OR ’human immunode-
ficiency virus’/exp OR ’human immunodeficiency virus’ OR
hiv:ti OR hiv:abOR ’hiv-1’:ti OR ’hiv-1’:abOR ’hiv-2’:ti OR
’hiv-2’:abOR ’human immunodeficiency virus’:tiOR ’human
immunodeficiency virus’:ab OR ’human immunedeficiency
virus’:ti OR ’human immunedeficiency virus’:ab OR ’human
immune-deficiency virus’:ti OR ’human immune-deficiency
virus’:ab OR ’human immuno-deficiency virus’:ti OR ’hu-
man immuno-deficiency virus’:ab OR ’acquired immunod-
eficiency syndrome’:ti OR ’acquired immunodeficiency syn-
drome’:abOR ’acquired immuno-deficiency syndrome’:tiOR
’acquired immuno-deficiency syndrome’:abOR ’acquired im-
mune-deficiency syndrome’:ti OR ’acquired immune-defi-
ciency syndrome’:ab OR ’acquired immunedeficiency syn-
drome’:ti OR ’acquired immunedeficiency syndrome’:ab
371108
Appendix 3. The Cochrane Library search strategy and results
Title: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Database: CLIB (2010 - 2012)
Date: 3 February 2012
ID Search Hits
#1 MeSH descriptor HIV Infections explode all trees 6499
#2 MeSH descriptor HIV explode all trees 2172
#3 hiv OR hiv-1* OR hiv-2* OR hiv1 OR hiv2 OR HIV
INFECT* OR HUMAN IMMUNODEFICIENCY
VIRUS OR HUMAN IMMUNEDEFICIENCY VIRUS
OR HUMAN IMMUNE-DEFICIENCY VIRUS
OR HUMAN IMMUNO-DEFICIENCY VIRUS
OR HUMAN IMMUN* DEFICIENCY VIRUS OR
ACQUIRED IMMUNODEFICIENCY SYNDROME
OR ACQUIRED IMMUNEDEFICIENCY SYNDROME
OR ACQUIRED IMMUNO-DEFICIENCY
SYNDROME OR ACQUIRED IMMUNE-
DEFICIENCY SYNDROME OR ACQUIRED IMMUN*
DEFICIENCY SYNDROME
10597
#4 MeSH descriptor Lymphoma, AIDS-Related, this term only 21
#5 MeSH descriptor Sexually Transmitted Diseases, Viral, this
term only
22
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(Continued)
#6 (#1 OR #2 OR #3 OR #4 OR #5) 10671
#7 MeSH descriptor Conjunctiva, this term only 473
#8 conjunctiva*:ti,ab,kw 1906
#9 (#7 OR #8) 1906
#10 MeSH descriptor Carcinoma, Squamous Cell, this term
only
1818
#11 carcinoma*:ti,ab,kw OR neoplasia:ti,ab,kw OR
neoplasm*:ti,ab,kw
42921
#12 (#10 OR #11) 42921
#13 (#6 AND #9 AND #12) 2
#14 (#6 AND #9 AND #12), from 2010 to 2012 0
Appendix 4. WHO International Clinical Trials Registry Platform (ICTRP) search terms and results
Title: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Database: WHO International Clinical Trials Registry Platform (ICTRP) 2010 - 2012
Date: 10 February 2012
No results were found for: hiv AND carcinoma AND conjunctiva
Appendix 5. National Institutes for Health (NIH) Clinical Trials registry search terms and results
Title: Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals
Database: Clinicaltrials.gov
Date: 10 February 2012
Found no studies with search of: “squamous cell carcinoma” AND conjunctiva AND hiv
WH A T ’ S N E W
Last assessed as up-to-date: 19 February 2007.
Date Event Description
11 December 2012 New citation required but conclusions have not
changed
New comprehensive searches, review updated.
11 December 2012 New search has been performed Updated
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H I S T O R Y
Protocol first published: Issue 1, 2006
Review first published: Issue 2, 2007
Date Event Description
29 October 2008 Amended Converted to new review format.
19 February 2007 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
SG developed the review topic idea. JI looked through search outputs, provided input, guidance and mentoring.
D E C L A R A T I O N S O F I N T E R E S T
Stephen Gichuhi has received funding to conduct a trial in this field (Gichuhi 2012).
S O U R C E S O F S U P P O R T
Internal sources
• University of Nairobi, Department of Ophthalmology, Kenya.
External sources
• South African Cochrane Centre HIV/AIDS Mentoring Programme, South Africa.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Carcinoma, Squamous Cell [∗therapy]; Conjunctival Neoplasms [∗therapy]; HIV Infections [∗complications]
MeSH check words
Humans
20Interventions for squamous cell carcinoma of the conjunctiva in HIV-infected individuals (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
